Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of CRVS is 28 and suggests 26% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell